IL312214A - Multispecific binding moieties comprising pd-1 and tgf-brii binding domains - Google Patents

Multispecific binding moieties comprising pd-1 and tgf-brii binding domains

Info

Publication number
IL312214A
IL312214A IL312214A IL31221424A IL312214A IL 312214 A IL312214 A IL 312214A IL 312214 A IL312214 A IL 312214A IL 31221424 A IL31221424 A IL 31221424A IL 312214 A IL312214 A IL 312214A
Authority
IL
Israel
Prior art keywords
brii
tgf
multiple specific
specific binding
binding domains
Prior art date
Application number
IL312214A
Other languages
English (en)
Hebrew (he)
Inventor
Cecilia Anna Wilhelmina Geuijen
Patrick Mayes
Shaun M Stewart
Liang-Chuan Wang
Original Assignee
Incyte Corp
Merus Nv
Cecilia Anna Wilhelmina Geuijen
Patrick Mayes
Shaun M Stewart
Wang liang chuan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp, Merus Nv, Cecilia Anna Wilhelmina Geuijen, Patrick Mayes, Shaun M Stewart, Wang liang chuan filed Critical Incyte Corp
Publication of IL312214A publication Critical patent/IL312214A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL312214A 2021-11-19 2022-11-18 Multispecific binding moieties comprising pd-1 and tgf-brii binding domains IL312214A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2029844 2021-11-19
PCT/EP2022/082377 WO2023089083A1 (en) 2021-11-19 2022-11-18 Multispecific binding moieties comprising pd-1 and tgf-brii binding domains

Publications (1)

Publication Number Publication Date
IL312214A true IL312214A (en) 2024-06-01

Family

ID=80625531

Family Applications (1)

Application Number Title Priority Date Filing Date
IL312214A IL312214A (en) 2021-11-19 2022-11-18 Multispecific binding moieties comprising pd-1 and tgf-brii binding domains

Country Status (18)

Country Link
US (1) US20230159645A1 (https=)
EP (1) EP4433505A1 (https=)
JP (1) JP2024542879A (https=)
KR (1) KR20240101664A9 (https=)
CN (2) CN118265725A (https=)
AR (1) AR127714A1 (https=)
AU (1) AU2022389596A1 (https=)
CA (1) CA3231649A1 (https=)
CL (1) CL2024001410A1 (https=)
CO (1) CO2024006325A2 (https=)
CR (1) CR20240201A (https=)
EC (1) ECSP24039278A (https=)
IL (1) IL312214A (https=)
MX (1) MX2024006018A (https=)
PE (1) PE20241477A1 (https=)
TW (1) TW202328180A (https=)
UY (1) UY40028A (https=)
WO (1) WO2023089083A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240343805A1 (en) * 2023-04-14 2024-10-17 Incyte Corporation USE OF AN ANTI-TGFßR2/PD-1 BISPECIFIC ANTIBODY

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
WO2018129331A1 (en) * 2017-01-07 2018-07-12 Merck Patent Gmbh Dosing regimens and dosage forms for targeted tgf-b inhibition
MX2020000055A (es) * 2017-07-06 2020-08-06 Merus Nv Anticuerpos biespecificos antiproteina 1 de muerte celular programada (pd-1) -anti inmunoglobulina de celulas t y dominio de mucina que contiene -3 (tim-3).
AU2018296067B2 (en) * 2017-07-06 2021-06-10 Merus B.V. Binding molecules that modulate a biological activity expressed by a cell
CN116199780A (zh) * 2019-12-24 2023-06-02 美勒斯公司 TGF-β-RII结合蛋白质
CN113563473A (zh) * 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
US20220144956A1 (en) * 2020-11-06 2022-05-12 Xencor, Inc. HETERODIMERIC ANTIBODIES THAT BIND TGFbetaRII

Also Published As

Publication number Publication date
CO2024006325A2 (es) 2024-06-27
CL2024001410A1 (es) 2024-08-30
US20230159645A1 (en) 2023-05-25
WO2023089083A1 (en) 2023-05-25
UY40028A (es) 2023-05-31
AU2022389596A1 (en) 2024-05-30
CN118265725A (zh) 2024-06-28
PE20241477A1 (es) 2024-07-17
ECSP24039278A (es) 2024-07-31
KR20240101664A (ko) 2024-07-02
JP2024542879A (ja) 2024-11-18
MX2024006018A (es) 2024-07-29
EP4433505A1 (en) 2024-09-25
AR127714A1 (es) 2024-02-21
CN119613560A (zh) 2025-03-14
TW202328180A (zh) 2023-07-16
CR20240201A (es) 2024-07-15
CA3231649A1 (en) 2023-05-25
KR20240101664A9 (ko) 2025-12-10

Similar Documents

Publication Publication Date Title
IL287479A (en) Cd19 binding molecules and uses thereof
DK3820569T3 (da) Antistofmolekyler der binder pd-l1 og cd137
IL272524A (en) Clec9a binding agents and use thereof
DK3472207T3 (da) Bindingsmolekyler, der binder pd-l1 og lag-3
EP3664829A4 (en) LIAISON OFFICERS AT PD-1 AND PD-L1
MA56029A (fr) Molécules de liaison au tigit et pd-1/tigit
EP3768664A4 (en) SHP2 INHIBITORS AND USES THEREOF
IL291007A (en) Cd8 binding agents and uses thereof
SI3877376T1 (sl) Spojine piridazinona in njihove uporabe
PL3370768T3 (pl) Przeciwciała specyficznie wiążące pd-1 i ich zastosowania
DK3939658T3 (da) Substitueret benzopyrrol og strukturelt relaterede komplementinhibitorer
PL3456346T3 (pl) Cząsteczki wiążące pd-1 i lag-3 oraz sposoby ich zastosowania
DK3536698T3 (da) Lanosterol-prodrugforbindelse og anvendelse deraf
IL284926A (en) Cd3-specific binding molecules
IL299867A (en) Cd19 binding molecules and uses thereof
EP3931213A4 (en) DNA BINDING DOMAIN TRANSACTIVATORS AND THEIR USES
EP3794039A4 (en) PD-1 BINDING ANTIBODIES AND USE
EP4073659A4 (en) ENHANCED PAGE INFORMATION COPROCESSOR
IL289531A (en) Cd38-binding agents and uses thereof
EP4428153A4 (en) GPRC5D-BINDING ANTIBODIES AND THEIR USES
EP3843741A4 (en) IRE1 KINASE INHIBITORS AND USES THEREOF
EP3774922A4 (en) BINDING MOLECULES INVOLVING CELLS
IL312214A (en) Multispecific binding moieties comprising pd-1 and tgf-brii binding domains
IL311771A (en) Multispecific binding agents against pd-l1 and cd137 in combination
IL312263A (en) Lurbinectedin and atezolizumab combinations